Principal Investigator
Byron Lam
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230561
Clinical Trial Summary
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and
Tolerability of ATSN-201 Gene Therapy in Male Subjects with RS1-Associated X-linked
Retinoschisis (LIGHTHOUSE)
Phase
TBD
Funding Agency/Sponsor
Intramural
Disease
Other